tirzepatide cardiovascular trial Cardiorenal Outcomes With Compared With Dulaglutide in Patients With Diabetes and Disease A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Compared with the GLP-1 agonist dulaglutide, the dual Diabetes drugs semaglutide and tirzepatide

doi: 10.1093/rheumatology/kep287 66 GladmanDNashPGotoHBirtJLinC-YOrbaiA-Met al

The global GLP-1 receptor agonist market size was calculated at USD 62.86 billion in 2025, grew to USD 73.86 billion in 2026, and is projected to reach around USD 315.33 billion by 2035

Discard it safely and request a replacement from your licensed 503A compounding pharmacy

The reported mass reflects the complete tirzepatide molecule: the 39-amino-acid peptide backbone with two Aib substitutions, plus the C20 fatty diacid lipid tail, plus the -glutamic acid and two ADO spacer units connecting the lipid to lysine 20, plus the C-terminal serinamide

Laboratory research record on GLP-1S [PMID: 38691645] PubMed laboratory record discussing GLP-1S in a research context